Business Wire

Waters Introduces Xevo TQ Absolute – The Most Sensitive and Compact Benchtop Tandem Quadrupole Mass Spectrometer

Share

Waters Corporation (NYSE:WAT) today introduced the new Xevo™ TQ Absolute system, the most sensitive and compact benchtop tandem mass spec in its class.i

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331005189/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The exceptionally sensitive Waters Xevo TQ Absolute tandem quadrupole mass spectrometer is up to 45% smaller, uses up to 50% less power and nitrogen, and generates up to 50% less heat than competing tandem quadrupole mass spectrometers. (Photo: Business Wire)

Waters’ newest high-performance mass spectrometer is up to 15X more sensitive for quantifying negatively ionizing compounds than its predecessorii and is 45% smaller and uses up to 50% less electricity and gas supply than other high-performance tandem quadrupole mass spectrometers available on the market.iii The Xevo TQ Absolute is designed to help pharmaceutical, food and beverage, and environmental analytical laboratories meet regulations requiring trace-level quantitative mass spectrometry analyses for a broad set of applications.

“The Xevo TQ Absolute is for laboratories looking for industry-leading quantitative sensitivity, accuracy, reproducibility, efficiency and sustainability,” said Jon Pratt, Waters Division Senior Vice President, Waters Corporation. “It offers more analytical firepower in a much smaller footprint than any other mass spec in its class, reaches exceptionally low limits of quantitation, and aids laboratory managers to best optimize their equipment utilization and analytical output.”

For optimal performance, Waters pairs the Xevo TQ Absolute mass spectrometer with Waters’ ACQUITY™ Premier UPLC System with MaxPeak™ HPS technology which eliminates non-specific adsorption of compounds containing phosphate and/or carboxylate groups and improves their recovery. Together, this integrated LC-MS/MS system is designed to drive the limits of quantitation to exceptionally low levels for many applications including:

  • Quantifying regulated impurities in drug products
  • Performing oligonucleotide bioanalytical assays
  • Measuring concentrations of endogenous metabolites in large cohort clinical studies
  • Quantifying residues and contaminants in food and environmental samples
  • Measuring low-level drugs and toxicants in physiological matrices
  • Detecting trace-level leachables from food packaging

The Xevo TQ Absolute incorporates thoughtful design features that enable consistent and reproducible analyses, allowing labs to maintain performance and uptime for longer periods in between routine cleaning and service intervals. This is achieved with new guidance on optimal probe positioning for both sensitivity and robustness and a source shield that helps minimize source contamination by the sample matrix or mobile phase salts.

The Xevo TQ Absolute is optimized for use with the waters_connect™ software platform and is also compatible with Waters MassLynx™ mass spectrometry software. For laboratories painstakingly reviewing the results from large numbers of samples, or those quantifying hundreds of small molecule components and contaminants in a single run, the MS Quan app on waters_connect and its unique Exception Focused Review (XFR) functionality, lets scientists review data in up to half the time it used to take themiv.

Worldwide customer shipments of the Xevo TQ Absolute are expected to commence in May.

Additional Resources

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in more than 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.

Waters, Xevo, ACQUITY, MaxPeak, MassLynx and waters_connect are trademarks of Waters Corporation.

______________________
i Based on a comparison of the sensitivity and product specifications of currently available instruments on the market
iiWaters Xevo TQ- XS
iii Based on a comparison of product specifications for the Sciex 7500, Sciex 6500, Agilent 6495C and Thermo TSQ Altis
iv Estimate based on time on task comparison of a batch of pesticides in a food safety analysis

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Brian J. Murphy
PR Manager, Corporate Communications
Waters Corporation
brian_j_murphy@waters.com
+1 508-482-2614

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

HiddenA line styled icon from Orion Icon Library.Eye